Understanding the Impact: AbbVie's Strategic Acquisition of Landos Biopharma. In a significant move that promises to reshape the landscape of treatment for inflammatory and autoimmune diseases, AbbVie has announced its decision to acquire Landos Biopharma for an estimated total of $212 million. This acquisition not only highlights AbbVie's commitment to expanding its immunology portfolio but also underscores ...
ランドスバイオファーマに関するコメント
anyone jumping on the short? 🔥
⇒ $137.5M deal at $20.42/sh 💰💰
⇒ strengthens portfolio in inflammatory & autoimmune diseases
⇒ Adds lead asset NX-13 (Ph2 trial UC)
$ナベーション バイオ A(NUVB.US)$ to acquire AnHeart Therapeutics
⇒ all-stock transaction
⇒ transforms NUVB into late-stage global oncology company
⇒ Includes taletrectinib with ongoing trials NSCLC)
$ノボ・ノルディスク(NVO.US)$ to acquire Cardior Pharmaceuticals
⇒ 1.025 B euros deal 💰💰
⇒ strengthens pi...
In a significant move that promises to reshape the landscape of treatment for inflammatory and autoimmune diseases, AbbVie has announced its decision to acquire Landos Biopharma for an estimated total of $212 million. This acquisition not only highlights AbbVie's commitment to expanding its immunology portfolio but also underscores ...
Dow Jones· 2 mins ago
まだコメントはありません